Cohera, a medical device manufacturer based in Pittsburgh, Ohio, announced that it was able to raise $17 million in a Series D funding round. According to a press release by the company, funds from the latest round will be used to pursue commercialization of its TissuGlu surgical adhesive through a large-scale clinical trial.

In its press release, the company detailed how the TissuGlu system works. TissuGlu is a specialized adhesive designed to adhere flaps of tissue during surgery. The system is effective at reducing the amount of fluid buildup during recovery. Postoperative drains can have a negative impact on patient comfort and can increase patient recovery times.

Cash from the Series D round will also be used for in-vivo clinical trials of its Sylys Surgical Sealant. Sylys is designed to reduce colorectal leaking during operations.

Patrick Daly is the CEO of Cohera. In prepared remarks, he said, "Our products have the potential to revolutionize how patients recover from many types of large flap procedures." He continued, "From abdominoplasties and mastectomies to lymph node dissection in cancer patients and bowel procedures, our adhesive and sealant technologies will transform patient experiences."

In December of 2012, the United States Food and Drug Administration approved the company’s clinical trial to test the TissuGlu adhesive on 130 abdominal surgery patients. The device received CE Mark clearance from the European Union in 2011.

References

www.coheramedical.com